Valion Bio, Inc. cotiza a 1.68 USD y tiene una capitalización bursátil de $3M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically…
| Periodo | 2023-11 | 2023-08 | 2023-05 | 2023-03 |
|---|---|---|---|---|
| Real | $-629.00 | $-2975.00 | $-4675.00 | $-9775.00 |
| Estimado | $-2975.00 | $-3400.00 | $-4675.00 | $-13175.01 |
| Sorpresa | +78.9% | +12.5% | +0.0% | +25.8% |
| Métrica | VBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -52.9% | -40.4% | -12.5% |
| ROA | -28.1% | -32.0% | +3.9% |
| Current Ratio | 20.13 | 2.84 | +17.29 |
| Debt / Equity | — | 0.28 | — |